Medtronic PLC $MDT is Eubel Brady & Suttman Asset Management Inc.’s 6th Largest Position

Eubel Brady & Suttman Asset Management Inc. reduced its position in shares of Medtronic PLC (NYSE:MDT) by 2.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 328,225 shares of the medical technology company’s stock after selling 7,567 shares during the period. Medtronic comprises about 3.5% of Eubel Brady & Suttman Asset Management Inc.’s holdings, making the stock its 6th largest holding. Eubel Brady & Suttman Asset Management Inc.’s holdings in Medtronic were worth $31,529,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Brighton Jones LLC boosted its holdings in Medtronic by 1,368.0% in the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after purchasing an additional 37,265 shares during the period. Sivia Capital Partners LLC boosted its holdings in Medtronic by 9.6% in the second quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock valued at $380,000 after purchasing an additional 381 shares during the period. Jump Financial LLC purchased a new position in Medtronic in the second quarter valued at $299,000. Main Street Financial Solutions LLC boosted its holdings in Medtronic by 28.9% in the second quarter. Main Street Financial Solutions LLC now owns 14,356 shares of the medical technology company’s stock valued at $1,251,000 after purchasing an additional 3,218 shares during the period. Finally, HUB Investment Partners LLC boosted its holdings in Medtronic by 21.3% in the second quarter. HUB Investment Partners LLC now owns 19,226 shares of the medical technology company’s stock valued at $1,676,000 after purchasing an additional 3,376 shares during the period. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Medtronic Stock Down 1.1%

Shares of NYSE MDT opened at $76.12 on Friday. The company has a market capitalization of $97.73 billion, a price-to-earnings ratio of 21.20, a price-to-earnings-growth ratio of 1.81 and a beta of 0.62. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. The business has a 50-day moving average of $84.76 and a two-hundred day moving average of $93.64. Medtronic PLC has a 1 year low of $74.40 and a 1 year high of $106.33.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The business had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. During the same quarter in the previous year, the firm earned $1.38 earnings per share. The business’s revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, analysts forecast that Medtronic PLC will post 5.57 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, April 17th. Stockholders of record on Friday, March 27th were given a dividend of $0.71 per share. The ex-dividend date was Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.7%. Medtronic’s payout ratio is 79.11%.

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of Medtronic stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the sale, the executive vice president owned 32,768 shares in the company, valued at approximately $3,201,761.28. The trade was a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.26% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Barclays lifted their target price on Medtronic from $118.00 to $120.00 and gave the company an “overweight” rating in a report on Wednesday, April 1st. Evercore set a $106.00 target price on Medtronic and gave the company an “outperform” rating in a report on Thursday, April 9th. Weiss Ratings lowered Medtronic from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, April 21st. Needham & Company LLC reiterated a “buy” rating and issued a $120.00 target price on shares of Medtronic in a report on Thursday, March 26th. Finally, Piper Sandler decreased their target price on Medtronic from $105.00 to $91.00 and set a “neutral” rating for the company in a report on Wednesday, April 1st. Fifteen investment analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. According to data from MarketBeat, Medtronic currently has an average rating of “Moderate Buy” and a consensus price target of $107.80.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).